Comtess 200mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Entacapone

Available from:

Orion Pharma (UK

ATC code:

N04BX02

INN (International Name):

Entacapone

Dosage:

200mg

Pharmaceutical form:

Tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04090100; GTIN: 6432100003607 6432100003614

Patient Information leaflet

PACKAGE LEAFLET: INFORMATION FOR THE USER
COMTESS 200 MG FILM-COATED TABLETS
Entacapone
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Comtess is and what it is used for
2.
What you need to know before you take Comtess
3.
How to take Comtess
4.
Possible side effects
5.
How to store Comtess
6.
Contents of the pack and other information
1.
WHAT COMTESS IS AND WHAT IT IS USED FOR
Comtess tablets contain entacapone and are used together with levodopa
to treat Parkinson’s disease.
Comtess aids levodopa in relieving the symptoms of Parkinson's
disease. Comtess has no effect on
relieving the symptoms of Parkinson’s disease unless taken with
levodopa.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE COMTESS
DO NOT TAKE COMTESS
•
if you are allergic to entacapone or to peanut or soya or any of the
other ingredients of this
medicine (listed in section 6);
•
if you have a tumour of the adrenal gland (known as pheochromocytoma;
this may increase the
risk of severe high blood pressure);
•
if you are taking certain antidepressants (ask your doctor or
pharmacist whether your
antidepressive medicine can be taken together with Comtess);
•
if you have liver disease;
•
if you have ever suffered from a rare reaction to antipsychotic
medicines called neuroleptic
malignant syndrome (NMS). See section 4 Possible side effects for the
characteristics of NMS;
•
if you have ever suffered from a rare muscle disorder called
rhabdomyolysis which was not
caused by injury.
WARNINGS AND PRECAUTIONS
Talk to your doctor

Summary of Product characteristics

OBJECT 1
COMTESS 200 MG FILM-COATED TABLETS
Summary of Product Characteristics Updated 11-Jan-2017 | Orion Pharma
(UK) Limited
1. Name of the medicinal product
Comtess 200 mg film-coated tablets
2. Qualitative and quantitative composition
Each film-coated tablet contains 200 mg entacapone.
Excipient with known effect
Each film-coated tablet contains 0.53 mg soya lecithin.
For the full list of excipients, see section 6.1.
3. Pharmaceutical form
Film-coated tablet (tablet)
Brownish-orange, oval, biconvex film-coated tablet with "COMT"
engraved on one side.
4. Clinical particulars
4.1 Therapeutic indications
Entacapone is indicated as an adjunct to standard preparations of
levodopa/benserazide or
levodopa/carbidopa for use in adult patients with Parkinson's disease
and end-of-dose motor fluctuations,
who cannot be stabilised on those combinations.
4.2 Posology and method of administration
Entacapone should only be used in combination with
levodopa/benserazide or levodopa/carbidopa. The
prescribing information for these levodopa preparations is applicable
to their concomitant use with
entacapone.
Posology
One 200 mg tablet is taken with each levodopa/dopa decarboxylase
inhibitor dose. The maximum
recommended dose is 200 mg ten times daily, i.e. 2,000 mg of
entacapone.
Entacapone enhances the effects of levodopa. Hence, to reduce
levodopa-related dopaminergic adverse
reactions, e.g. dyskinesias, nausea, vomiting and hallucinations, it
is often necessary to adjust levodopa
dosage within the first days to first weeks after initiating
entacapone treatment. The daily dose of
levodopa should be reduced by about 10-30% by extending the dosing
intervals and/or by reducing the
amount of levodopa per dose, according to the clinical condition of
the patient.
If entacapone treatment is discontinued, it is necessary to adjust the
dosing of other antiparkinsonian
treatments, especially levodopa, to achieve a sufficient level of
control of the parkinsonian symptoms.
Entacapone increases the bioavailability of levodopa from standard